Sun Pharma Introduces FEXUCLUE® for Erosive Esophagitis Treatment in India

Sun Pharmaceutical Industries Limited (Sun Pharma) has introduced FEXUCLUE® (Fexuprazan) 40 mg tablets in India. This new drug, a potassium-competitive acid blocker (P-CAB), is designed to treat Erosive Esophagitis in adults. FEXUCLUE® offers fast action, stable gastric acid suppression, and can be taken with or without food.

Key Benefits of FEXUCLUE®

• Fast Onset & Long-Lasting Effect: Fexuprazan works quickly and has the longest half-life (9 hours) among P-CABs, ensuring prolonged acid suppression and better night-time symptom relief.
• Clinically Proven: In a Phase 3 clinical trial in India, the drug helped over 95% of patients heal from Erosive Esophagitis within 8 weeks. It was also well tolerated among Indian patients.

Agreement with Daewoong Pharmaceutical

Sun Pharma has partnered with Daewoong Pharmaceutical Co Ltd, a South Korean company, to manufacture and sell FEXUCLUE® in India. Under this agreement, Daewoong will receive upfront and milestone payments, including royalties.

Kirti Ganorkar, CEO of Sun Pharma’s India Business, highlighted that Erosive Esophagitis significantly affects patients’ quality of life and that FEXUCLUE® is a best-in-class treatment that addresses an unmet need in managing this condition.

Understanding Erosive Esophagitis

Erosive Esophagitis occurs when the esophagus lining becomes inflamed and damaged due to prolonged exposure to stomach acid. It is considered a form of gastroesophageal reflux disease (GERD) and is linked to heartburn and regurgitation.

• Prevalence in India: GERD affects 7.6% to 30% of the population, and 9% of GERD patients develop Erosive Esophagitis.
• Current Treatment Challenges: Despite various medical, surgical, and endoscopic treatments, many patients still struggle with symptom relief and quality of life issues.

About Sun Pharma

Sun Pharma is India’s largest pharmaceutical company and a global leader in specialty generics. It operates in over 100 countries and has a strong presence in dermatology, ophthalmology, and oncology-related treatments.

As of April 7, 2025, at 10:16 AM IST, Sun Pharmaceutical Industries share price is trading at ₹1,651.75, down ₹57.60 (3.37%) for the day. The stock opened at ₹1,620.10, reached a high of ₹1,685.35, and touched a low of ₹1,620.10. Sun Pharma has a market capitalisation of ₹3.96 lakh crore, a P/E ratio of 34.61, and a dividend yield of 0.94%. The stock’s 52-week high stands at ₹1,960.35, while its 52-week low is ₹1,377.20.

Read more about Siemens Share Price Drops 50% Post-Demerger with Siemens Energy India.

About Daewoong Pharmaceutical

Daewoong Pharmaceutical is a leading South Korean healthcare company known for its research in new drug development. It launched Fexuprazan for GERD in 2022 and introduced a diabetes drug, Enavogliflozin, in 2023.

Conclusion

With FEXUCLUE®, Sun Pharma strengthens its commitment to innovative treatments in gastroenterology. This launch offers new hope for patients struggling with Erosive Esophagitis.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.